4 completed, 1 terminated. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
Follow lomibuvir: new trials by email Literature Review of lomibuvir trials Research Report on lomibuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C VX-222, telaprevir, ribavirin - Chronic Hepatitis C Virus | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 64 | 2012-07-01 | 2014-07-04 |
| A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis VX-222, telaprevir, ribavirin - Chronic Hepatitis C Virus | Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 103 | 2012-02-01 | 2014-10-20 |
| A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection telaprevir, VX-222, ribavirin - Chronic Hepatitis C Virus Infection | Phase 2 | Terminated | Vertex Pharmaceuticals Incorporated | 152 | 2010-08-01 | 2020-09-30 |
| Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects VCH-222, telaprevir - Hepatitis C | Phase 1 | Completed | Vertex Pharmaceuticals Incorporated | 30 | 2009-08-01 | 2010-01-07 |
| Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection VCH-222 or matching placebo, peginterferon alfa-2a, ribavirin - Hepatitis C | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 49 | 2009-04-01 | 2014-03-10 |
Hepatitis C (2) · Hepatitis C, Chronic (2)
Vertex Pharmaceuticals Incorporated (5)
United States (4) · Canada (2) · New Zealand (2) · Argentina (1) · Germany (1) · Poland (1) · Puerto Rico (1) · United Kingdom (1)